Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-09, Stock:NVO, The news for the past five days is as follows:
2018-03-02: NEWS1: Sanofi’s Established Prescription Products in 4Q17.NEWS2: Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices.NEWS3: Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices.
2018-03-05: NEWS1: Oral Semaglutide May Drive Solid Growth for NVO Going Forward.NEWS2: Ozempic Is Expected to Boost GLP-1 Drug Class Trajectory in 2018.NEWS3: Alexion Pharmaceuticals: Strensiq and Kanuma in 2017.NEWS4: Analyst Ratings and Recommendations for Sanofi.NEWS5: Victoza Continues to Lead in the GLP-1 Segment in 2018.NEWS6: GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk.NEWS7: OZEMPIC® now available for Canadians with type 2 diabetes.
2018-03-06: NEWS1: Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care.NEWS2: Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care.NEWS3: Diabetes Care Segment Continues to Drive Growth for NVO in 2018.NEWS4: Novo Nordisk Focuses on Raising the Bar in Research in 2018.
2018-03-07: NEWS1: Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits.NEWS2: Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits.NEWS3: Tresiba Emerged as a Blockbuster Therapy in 2017.NEWS4: Tresiba Emerged as a Blockbuster Therapy in 2017.NEWS5: Will NVO Continue to Lead the Global Insulin Market in 2018?.NEWS6: Will NVO Continue to Lead the Global Insulin Market in 2018?.
2018-03-08: NEWS1: Novo Nordisk Focuses on Expanding Semaglutide’s Label.NEWS2: Novo Nordisk Focuses on Expanding Semaglutide’s Label.NEWS3: Label Expansion May Boost Xultophy’s Sales in 2018.NEWS4: Label Expansion May Boost Xultophy’s Sales in 2018.NEWS5: Saxenda May Continue to Lead in the Diabetes Segment in 2018.NEWS6: Saxenda May Continue to Lead in the Diabetes Segment in 2018.NEWS7: Xultophy May Prove a Strong Growth Driver for NVO in 2018.NEWS8: Xultophy May Prove a Strong Growth Driver for NVO in 2018.NEWS9: Novo Nordisk Has Developed a Portfolio of New-Generation Insulins.NEWS10: Novo Nordisk Has Developed a Portfolio of New-Generation Insulins.

Answer: Decrease